Welcome to our dedicated page for Boston Scientific news (Ticker: BSX), a resource for investors and traders seeking the latest updates and insights on Boston Scientific stock.
Boston Scientific Corp. (BSX) is a leading global medical technology company that specializes in the development, manufacture, and marketing of medical devices for interventional medical procedures. The company's operations are divided into two main segments: MedSurg and Cardiovascular. With a focus on less invasive medical devices, Boston Scientific's products are designed for insertion into the human body through small openings or cuts, making them essential in various medical fields.
The company's product portfolio includes devices for angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and the treatment of incontinence. Boston Scientific markets its innovative solutions to healthcare professionals and institutions worldwide, with nearly half of its total sales coming from foreign markets.
Recently, the company made headlines with a successful public offering of €2,000,000,000 in aggregate principal amount of notes. These funds are intended to finance the acquisition of Axonics, Inc. and to repay existing debt, showcasing Boston Scientific's strategic financial management.
Significant advancements include the FDA approval for the AGENT™ Drug-Coated Balloon (DCB), aimed at treating coronary in-stent restenosis in patients with coronary artery disease. This novel device marks the first drug-coated coronary balloon available in the U.S., providing a dedicated treatment option for this challenging condition.
Boston Scientific is also expanding its strategic cooperation with Scivita Medical Technology Co., Ltd., focusing on the development and global distribution of endoscopic devices. This collaboration underscores the company's commitment to advancing medical technologies that enhance patient care.
On the financial front, Boston Scientific reported net sales of $3.856 billion for the first quarter of 2024, a 13.8% increase from the previous year. The company's diverse portfolio and robust pipeline, including the recent launch of the FARAPULSE™ Pulsed Field Ablation System, have been key drivers of this growth.
Looking ahead, Boston Scientific is actively involved in clinical trials such as the NAVIGATE-PF study for the FARAWAVE™ Nav Pulsed Field Ablation Catheter and the MODULAR ATP trial for the mCRM™ System. These trials aim to further improve patient outcomes and expand the company's product offerings.
As a global leader in medical technology, Boston Scientific remains committed to transforming lives through innovative solutions that address unmet patient needs and reduce healthcare costs. Stay updated with the latest developments by visiting their website and connecting on LinkedIn and X, formerly Twitter.
Boston Scientific Corporation reported net sales of $3.389 billion for Q1 2023, a rise of 12.0% year-over-year, exceeding guidance of 3-5%. The company achieved a GAAP net income of $300 million or $0.21 per share, up from $97 million or $0.07 per share in the prior year. Adjusted EPS was $0.47, surpassing guidance of $0.42 to $0.44. Key growth areas included U.S. sales with a 12.7% increase, and 20.2% growth in emerging markets. The company introduced several innovative medical devices, including the LithoVue™ Elite and POLARx™ FIT systems. Full-year sales growth is projected at 8.5% to 10.5%, with adjusted EPS expected between $1.90 to $1.96. A conference call will provide further insights.
Boston Scientific Corporation (NYSE:BSX) released its 2022 Performance Report, highlighting advancements in medical technologies alongside environmental and social governance (ESG) commitments. The company invested over $1.3 billion in R&D and improved the lives of 33 million patients globally. Among key achievements, it became one of the first in its sector to have a net-zero target approved under the Science Based Targets initiative. Boston Scientific reached 76% renewable electricity usage and is on track for carbon neutrality by 2030. The report also showcased progress in diversity, with 42.6% of managerial roles held by women. The company emphasized its commitment to sustainability and social equity while delivering improved operational capabilities.
Boston Scientific emphasizes the importance of diversity, equity, and inclusion (DEI) as a business imperative in the medical device industry. After evaluating employee feedback in 2017, leadership recognized that many female employees felt overlooked for promotions compared to their male counterparts. This realization prompted a commitment to improve DEI within the organization, as fostering a diverse workplace enhances innovation and problem-solving capabilities. The company believes that understanding the unique challenges faced by patients and customers requires diverse perspectives, ultimately driving creativity in product development.
Boston Scientific emphasizes its commitment to improving lives through innovative deep brain stimulation (DBS) products, particularly for patients with Parkinson's disease (PD). The company showcases the passion of its employees, such as Nicky Nault, who personally connects with patients, and Celine Constant, who empowers PD patients through education. Benny Yeh leads the R&D division, ensuring that all DBS products meet high-quality standards. The firm supports Parkinson's Awareness Month by highlighting these employees' stories, illustrating their dedication to patient care. DBS therapy aims to reduce medication needs and improve motor functions for PD patients, enhancing their quality of life.
FAQ
What is the current stock price of Boston Scientific (BSX)?
What is the market cap of Boston Scientific (BSX)?
What does Boston Scientific Corp. specialize in?
What are the main segments of Boston Scientific?
What recent financial achievement has Boston Scientific announced?
What is the AGENT™ Drug-Coated Balloon (DCB)?
What is the focus of Boston Scientific’s latest clinical trials?
How has Boston Scientific performed financially in 2024?
What are some key products manufactured by Boston Scientific?
How much of Boston Scientific’s sales come from international markets?
Who are Boston Scientific’s customers?
What is Boston Scientific's vision for the future?
